Best OncoPharmPod Podcasts (2025)

1
SC Pembro, Biotin, P5-yr POLARIX data 18:00

Play Pause

1h ago18:00

18:00

The long awaited subcutaneous formulation of pembrolizumab is not FDA-approved. We discuss its administration and toxicity & PK differences vs. IV use.Biotin supplementation can interfere with lots of labs cancer patients get routinely - Who knew? (Ahem, not me.) Link: https://doi.org/10.1200/OP-25-00693POLARIX 5-year Data: https://doi.org/10.1200/…

1
ALASCCA 12:33

3d ago12:33

12:33

We discuss the ALASCCA study (Adjuvant Low-doseASpirin in Colorectal CAncerBy John Bossaer

1
EGFRm NSCLC Updates 13:41

13d ago13:41

13:41

The 2025 World Conference on Lung Cancer just concluded, and there are several notable updates concerning treatment of EGFR-mutated NSCLC.1. The COMPEL study tries to find the value of continuing osimertinib (with the addition of chemotherapy) after progression on osimertinib. The results are, well, compelling!2/3. We now have updates on the OS ben…

1
Time to Cilta-Cel-ebrate? 10:25

20d ago10:25

10:25

The 5-year+ follow-up from CARTITUDE-1 has people asking if cilta-cel can cure multiple myeloma? We discuss this data and the broad comparison to the other BCMA-targeting CAR-T product, idi-cel and a recent comparison on plasma cell leukemia.CARTITUDE-1 Long-Term F/U: https://doi.org/10.1200/JCO-25-00760Cilta-cel & ide-cel in plasma cell leukemia: …

1
RNA Vaccine Potential as a Cancer Treatment 11:25

27d ago11:25

11:25

The potential breakthrough in RNA vaccine technology has been increasingly discussed on social media. This episode looks at one promising study and its early, early results so far.UF GBM study: https://doi.org/10.1016/j.cell.2024.04.003RNA Treatment Vaccine Review: https://doi.org/10.1002/ctm2.1384By John Bossaer

1
Venetoclax Dosing & APOLLO 17:47

1M ago17:47

17:47

Malignant Hematology Updates:Venetoclax dosing strategies continue to evolveHMA/Ven + IDH1/2 inhibitors: https://doi.org/10.1200/JCO-25-00640HMA/Ven + revumenib: https://doi.org/10.1200/JCO-25-00914Venetoclax + CPX-351: https://doi.org/10.1002/ajh.27723APOLLO: https://doi.org/10.1200/JCO-25-00535Iland APOLLO editorial: https://doi.org/10.1200/JCO-2…

1
Zongertinib 12:07

1M ago12:07

12:07

A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.By John Bossaer

1
Dordaviprone & RCT to prevent ADRs 11:30

2M ago11:30

11:30

This week's episode discusses the first-in-class agent, dordaviprone and a randomized control trial that demonstrated an oncology pharmacists led to decreased rates of adverse drug reactions (ADRs) in a Hem/Onc clinic.Dordaviprone data: https://doi.org/10.1200/jco.23.01134Alabassi AK, et al. Role of a designated pharmacist in reducing adverse drug …

1
ProMACE-CytaBOM 10:21

2M ago10:21

10:21

More isn't always better. Our Landkmarks of OncoPharm series covers lessons learned from the ProMACE-CytaBOM regimen for NHL.ProMACE-CytaBOM: https://www.annalsofoncology.org/article/S0923-7534(20)31592-1/pdfRCT vs. CHOP (& others): https://www.nejm.org/doi/full/10.1056/NEJM199304083281404By John Bossaer

1
Testicular Cancer in a Nutshell 11:19

2M ago11:19

11:19

A brief overview of testicular cancerBy John Bossaer

1
Supportive Care Updates 11:12

3M ago11:12

11:12

A few supportive care updates:1. Skin prophylaxis to prevent severe dermatologic toxicity with Nivo/Ipi.Note* published in JCO Oncology Practice (NOT JAMA Oncol as stated in the episodeLink: https://doi.org/10.1200/OP-25-001002. Stampede-Metformin and how metformin has some beneficial effects in prostate cancer patients who don't have diabetesLink:…

1
Linvoseltamab & sunvozertinib 9:36

3M ago9:36

9:36

Two new drug approvals to talk about (after I misplaced my notes!)By John Bossaer

1
Antiandrogen Withdrawal 9:53

3M ago9:53

9:53

Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?By John Bossaer

1
June 2025 Updates 27:37

3M ago27:37

27:37

A plethora of recent updates:-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689)-Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib-Pirtobrutinib improves PFS in CLL-Zanubrutinib has a new dosage form on the way-Another mitomycin product approved with "reverse thermal properties"-A new regimen for FL o…

1
ASCO 2025 14:15

4M ago14:15

14:15

A recap of notable updates from ASCO 20251. Destiny-Breast092. BREAKWATER3. ATOMIC4. Delphi-3045. CM 816 OS update6. C-POST7. MatterhornBy John Bossaer

1
CLEOPATRA 11:17

4M ago11:17

11:17

Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a standard first-line regimen for metastatic HER2-amplified breast cancer.By John Bossaer

1
Talking about cancer misinformation 15:27

4M ago15:27

15:27

If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you.1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.218572. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526…

1
Four New Drugs 12:20

4M ago12:20

12:20

Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.By John Bossaer

1
Mg to Prevent Cisplatin Kidney Injury 15:48

5M ago15:48

15:48

A splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury.Gupta et al. JAMA Oncol (2025): doi:10.1001/jamaoncol.2025.0756PRAGMATIC. ESMO Open (2022): https://doi.org/10.1016/j.esmoop.2021.100351Yamamoto et al. Anticancer Res (2015): https://pubmed.ncbi.nlm.nih.gov/25862878/…

1
TI-CH, Updates on dostarlimab, ventoclax, & zongertinib 12:11

5M ago12:11

12:11

This episode summarizes recent updates on:Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361)Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.105…

1
BRCA Reversion Mutations 12:43

5M ago12:43

12:43

BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors.Bibliography:1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-07152: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.009333: Elucidating acquired PARP inhibitor resistance in advanced pr…

1
HOPA 25 Recap 11:45

5M ago11:45

11:45

Recapping HOPA 25 and Portland*Great food (not discussed, the most excellent ETSU dinner at Arden)*COCOON*Pharmacists make everyone's job easier and keep patients out of the ED*A few more tidbits too!By John Bossaer

1
Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview 12:25

6M ago12:25

12:25

FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.By John Bossaer

1
API-CAT & IMPROVE 12:42

6M ago12:42

12:42

We discuss reduced dose apixaban for months 6+ of treating cancer-associated VTE (API-CAT) and the impact (or lack thereof) of pausing BTK-inhibitors around vaccination (IMPROVE)By John Bossaer

1
Topotecan 9:46

6M ago9:46

9:46

A Foundations of OncoPharm episode on Topotecan. (Originally to be released week of 3/27)By John Bossaer

1
Keynote 811 Update 12:59

6M ago12:59

12:59

The updated Keynote 811 OS results convert an accelerated approval for pembrolizumab to a regular approval, albeit restricted by PD-L1 CPS status of 1 or higher.By John Bossaer

1
Polar: Cryotherapy or Compression to Prevent Taxane-induced neuropathy 9:59

7M ago9:59

9:59

There is a decent track record with mixed results for cryotherapy to prevent taxane-induced peripheral neuropathy. The POLAR trial adds to this body of evidence that trends in favor of cryotherapy. Compression therapy is another alternative. Both are studied in POLAR.POLAR: doi:10.1001/jamaoncol.2025.0001…

1
About Herb Drug Interactions 11:48

7M ago11:48

11:48

Ten of the top herb-chemotherapy interactions.About Herbs website: https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs/searchAlso, search 'About Herbs' in your app store.By John Bossaer

1
Rethinking Premeds 8:35

7M ago8:35

8:35

Two recent publications suggest modifications to standard subcutaneous daratumumab pre-meds is safe...and saves time!Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470We end summarizing some emerging evidence about the need, or lac…

1
AMPLIFY 17:25

7M ago17:25

17:25

We take a deep look at the recently published, and guideline changing, AMPLIFY trial of fixed-duration acalabrutinib in CLL.Link: DOI: 10.1056/NEJMoa2409804By John Bossaer

1
OncoPharm M & M: Fatal TLS & Fatal T-cell lymphoma post-CAR-T 12:35

8M ago12:35

12:35

Morbidity & Mortality (M & M) are common case conferences to learn from unfortunate cases to improve care in the future. This episode looks at two recently published case reports.1. Fatal tumor lysis syndrome following a lack of venetoclax ramp-up in AML: https://www.jhoponline.com/issue-archive/2024-issues/december-2024-vol-14-no-6/rapid-onset-of-…

1
[Re-release] Rituximab 18:34

8M ago18:34

18:34

Dipping into the archives (technology issues with new computer) to re-release the Foundations of OncoPharm episode on rituximab. Where did that 375 mg/m2 dose come from anyway?By John Bossaer

1
Acalabrutinb + BR and sotorasib + panitumumab 8:47

8M ago8:47

8:47

FDA approves two new treatment regimens:1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)By John Bossaer

1
Datoptamab deruxtecan 18:49

8M ago18:49

18:49

Datopotamab deruxtecan, a newly approved agent for breast cancer, is discussed.By John Bossaer

1
Dex Dosing in MM, Tec-Tal, & postMONARCH 12:17

9M ago12:17

12:17

HOPA Pharmacy Outcomes & Practice-Based Collaboration Survey: https://www.surveymonkey.com/r/MXNVRBRDexamethasone Dosing Intensity in Multiple Myeloma: https://doi.org/10.1182/blood.2024025939Talquetamab + Teclistamab: https://doi.org/10.1182/blood.2024025939postMONARCH: https://doi.org/10.1200/JCO-24-02086…

1
Breakwater, Ensartinib, & SC Nivo 10:52

9M ago10:52

10:52

We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.By John Bossaer

1
The Accelerated Approval Pathway 13:14

9M ago13:14

13:14

Weighing the Pros & Cons of the accelerated approval pathway as it relates to oncology. An updated draft guidance document from FDA regarding this pathway and some compelling data regarding the public's perceived value of newly approved drugs for cancer.Article: Preferences for speed of access versus certainty of the survival benefit of new cancer …

1
2024 New Drug Review 18:03

9M ago18:03

18:03

Looking back at new approvals from 2024 - what to keep, re-gift, or return?And yes, as soon as this was recorded 2 new drugs were approved.By John Bossaer

1
A Feast Of Updates 17:05

10M ago17:05

17:05

Lots of recent clinical trial updates to discuss:AQUILA: Daratumumab for high-risk smoldering multiple myelomaCheckmate 8HW: Nivo/Ipi for MSI-high/MMRd metastatic colorectal cancerDESTINY-Breast06: T-DXd in HER2-low MBC after hormonal treatment, but without previous chemo for MBCARMANI: Switch maintenance ramucirumab-paclitaxel in metastatic gastri…

1
Zenocutuzumab 12:45

10M ago12:45

12:45

A first-in-class approval of a bispecific HER2-HER3 monoclonal antibody for NRG1 fusion (+) NSCLC and pancreatic cancer.By John Bossaer

1
Revumenib 14:52

10M ago14:52

14:52

The 1st menin inhibitor, revumenib, is approved for relapsed/refractory acute leukemias.Understanding the Pathway: https://doi.org/10.1200/JCO-24-01265By John Bossaer

1
Anthracycline Use In Breast Cancer 9:52

11M ago9:52

9:52

A nice editorial succinctly summarizes a framework for thinking about how to incorporate anthracyclines into the treatment of early stage breast cancer patients. Anthracyclines in Early Breast Cancer: The Long Goodbye -https://doi.org/10.1200/JCO-24-0191610-year Outcomes of READ trial: https://doi.org/10.1200/JCO.24.00836Bonus - Practical Guide for…

1
SWISH 9:18

11M ago9:18

9:18

Reviewing the data to support use of dexamethasone solution mouthwash for PIK3/AKT/mTOR inhibitor-induced stomatitis, caused by drugs like everolimus, alpelisib, capivasertib, & inavolisib.SWISH: https://doi.org/10.1016/s1470-2045(17)30109-2Alliance MIST Trial: https://doi.org/10.1053/j.seminoncol.2023.01.001…

1
Zolbetuximab 19:30

11M ago19:30

19:30

The first Cldn 18.2 targeting monoclonal antibody has been improved. Let's talk about it!By John Bossaer

1
S1826 & INTERLACE 22:49

11M ago22:49

22:49

Discussing two excellent articles from earlier this month.S1826: N-AVD vs. Bv-AVD (DOI: 10.1056/NEJMoa2405888)& INTERLACE: induction chemo prior to concurrent cisplatin/RT in locally advanced cervical cancer (DOI: https://doi.org/10.1016/S0140-6736(24)01438-7)By John Bossaer

1
Inavolisib 16:42

12M ago16:42

16:42

A new PIK3Ca inhibitor is approved for breast cancer.By John Bossaer

1
Autumnal (2024) AML Updates 13:48

12M ago13:48

13:48

Reviewing 3 recent AML publicationsDouble-Dauno (90 mg/m2 vs. 60 mg/m2): https://doi.org/10.1200/JCO.24.00235AML60+ Risk Stratification: https://doi.org/10.1200/JCO.23.02631Decitabine-Ven as bridge to Allo HSCT: https://doi.org/10.1016/S2352-3026(24)00241-2By John Bossaer

1
MSI-High Rectal Cancer Treatment 10:03

12M ago10:03

10:03

MSI-high/MMRd rectal cancer treatment guidelines are being re-written. A brief synopsis of why treatment guidelines are changing so quickly in this space.Also, listeners helped out in explaining the ribociclib storage & stability change. Hint: https://www.novartis.com/news/novartis-implements-manufacturing-adjustments-ribociclib-ensure-alignment-la…

1
NATALEE + a slew of FDA updates 16:39

1y ago16:39

16:39

FDA has been busy the last week approving:-ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement-osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC-amivantamab + chemotherapy following progression on osimertinib (Mariposa-2)-a subcutaneous formul…

1
ESMO 2024 22:17

1y ago22:17

22:17

Recapping just some of the notable data coming out of ESMO 2024:-Final OS results from Keynote-522 (perioperative pembrolizumab in TNBC)-AMBASSADOR (adjuvant pembrolizumab in bladder cancer) -NIAGRA (perioperative durvalumab in bladder cancer)-ADRIATIC (discussed on ASCO recap Pod, but publication now available)-LEANOX (impact of lean body mass adj…